11/4/2025

Janusmed sex and gender

Janusmed sex and gender – Lenvatinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Lenvatinib

Lenvatinib

Class : C

Show all info

Print

Contact us

  1. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy. JAMA Intern Med. 2021;181(10):1351-1358.

  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.

  3. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9.

  4. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.

  5. Assessment report - Lenvima (lenvatinib). European Medicines Agency (EMA) [www]. [updated 2015-06-25, cited 2025-09-12].

  6. Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81(6):1124-33.

  7. Hu Y, Chen R, Ye Z, Wei F, Lin K, Liu J et al. Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. J Clin Pharmacol. 2022;62(12):1507-1517.

  8. Puliani G, Bianchini M, Giani C, Valerio L, Nervo A, Sapuppo G et al. Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study). Eur Thyroid J. 2025;14(2):.

  9. Lenvima (lenvatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-04-22, cited 20205-09-12]

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy. JAMA Intern Med. 2021;181(10):1351-1358.
  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.
  3. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9.
  4. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.
  5. Assessment report - Lenvima (lenvatinib). European Medicines Agency (EMA) [www]. [updated 2015-06-25, cited 2025-09-12].
  6. Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81(6):1124-33.
  7. Hu Y, Chen R, Ye Z, Wei F, Lin K, Liu J et al. Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. J Clin Pharmacol. 2022;62(12):1507-1517.
  8. Puliani G, Bianchini M, Giani C, Valerio L, Nervo A, Sapuppo G et al. Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study). Eur Thyroid J. 2025;14(2):.
  9. Lenvima (lenvatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-04-22, cited 20205-09-12]
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]